Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Non-Muscle Invasive Bladder Neoplasms × tislelizumab × Clear all

Phase

Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Small Cell Lung Carcinoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Breast Neoplasms 1

Interventions

tislelizumab 1 lornoxicam 1 Patient Discharge 1 Ofloxacin 1 Mitomycin 1 Epirubicin 1 Drainage 1 Doxorubicin 1 Accelerometry 1 5-aminolevulinic acid hexyl ester 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05580354 2022-10-14

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Ruijin Hospital

Phase 4 Unknown

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡